Cancer may have just met its match
A revolutionary approach to cancer fighting has the medical community buzzing. Here's how to profit.
Ever since the nation declared war on cancer, back in 1971 when President Richard Nixon signed the National Cancer Act, it's been an uphill battle. Cancer is still the second-leading cause of death in the U.S., behind heart disease.
Merrill Lynch predicts a 2015 launch for the drug, "reaching peak sales of $2 billion five years after launch, which implies a 35% share of the three markets in which nivolumab is currently in Phase III trials." (Merrill, like other firms, is not yet modeling the potential for this drug in other types of cancers that Bristol-Myers is not yet testing).
Analysts at UBS project $6 billion in annual sales, but caution that competitors are developing their own cancer immunotherapy drugs, which may cap the potential for nivolumab.
God bless a Repukelican free America!
Cancer is a CONDITION of your own cells due to genetics and the toxic environmental triggers emanating from modern conveniences.
YES - we must be prepared to die for the progress.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The apparel chain takes a hard hit after blaming the weather for its quarterly sales decline. But cold temperatures don't explain the drop in full-year sales as well.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.